Urinary incontinence is also called Overactive Bladder, and is due to the spastic contraction of smooth muscle in the bladder and urethra, causing frequent and strong urges to urinate, resulting in embarrassing incidents such a wetting accidents and frequent visits to the bathroom. This can affect sleep, social life, health and wellbeing and relationships among other problems.
The goal of therapy is to calm the spastic bladder muscle, and attempts to date have resulted in the development of therapies such as Detrol® (Pfizer), which has generated over $1.2B in sales. Detrol is a competitive muscarinic receptor antagonists, as are all other drugs on the market for the treatment of urinary incontinence.
Long term market growth will require a drug with a novel mechanism of action. According to Datamonitor, there is a significant untapped patient base in the US stress urinary incontinence market, and a drug entering this market would benefit from exclusivity being the only treatment approved for that indication in the US, giving access to a potential 28 million patient population base.
At ICBC we have developed compounds that we believe can act directly on the smooth muscle ion channels resulting in a relaxation of smooth muscle. We are currently in the early stages of development and testing of these compounds and hope to be able to work with industry in their commercialization.
Urinary incontinence is one of the most common chronic medical conditions seen in primary care practice and we hope to be part of the solution, to ease the suffering of patients with this condition.